Breaking News

Novatek Seeks EUA for TQ Formula to Treat COVID

Oral TQ Formula significantly improved total symptom burden in a Phase 2 Study of COVID-19 patients in the outpatient setting.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novatek Pharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company, announced topline results from a Phase 2 randomized, controlled multicenter trial (BOSS-Covid-19 study) evaluating the efficacy and safety of oral TQ Formula in COVID-19 patients in the outpatient setting.    The study demonstrated that oral TQ Formula led to significantly faster decline in total symptom burden, defined as duration and severity of symptoms over time from Day 1 through Day 14, relative to...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters